Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer.

Perilli L, Tessarollo S, Albertoni L, Curtarello M, Pastò A, Brunetti E, Fassan M, Rugge M, Indraccolo S, Amadori A, Bortoluzzi S, Zanovello P.

BMC Cancer. 2019 Aug 20;19(1):821. doi: 10.1186/s12885-019-5982-9.

2.

Circulating miRNA-375 as a potential novel biomarker for active Kaposi's sarcoma in AIDS patients.

Piano MA, Gianesello L, Grassi A, Del Bianco P, Mattiolo A, Cattelan AM, Sasset L, Zanovello P, Calabrò ML.

J Cell Mol Med. 2019 Feb;23(2):1486-1494. doi: 10.1111/jcmm.14054. Epub 2018 Dec 13.

3.

Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells.

Scaini MC, Pigozzo J, Pizzi M, Manicone M, Chiarion-Sileni V, Zambenedetti P, Rugge M, Zanovello P, Rossi E, Zamarchi R, Facchinetti A.

Melanoma Res. 2019 Feb;29(1):89-94. doi: 10.1097/CMR.0000000000000510.

PMID:
30222690
4.

Chemotactic Cues for NOTCH1-Dependent Leukemia.

Piovan E, Tosello V, Amadori A, Zanovello P.

Front Immunol. 2018 Apr 3;9:633. doi: 10.3389/fimmu.2018.00633. eCollection 2018. Review.

5.

A coordinate deregulation of microRNAs expressed in mucosa adjacent to tumor predicts relapse after resection in localized colon cancer.

Grassi A, Perilli L, Albertoni L, Tessarollo S, Mescoli C, Urso EDL, Fassan M, Rugge M, Zanovello P.

Mol Cancer. 2018 Jan 31;17(1):17. doi: 10.1186/s12943-018-0770-8.

6.

WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia.

Bordin F, Piovan E, Masiero E, Ambesi-Impiombato A, Minuzzo S, Bertorelle R, Sacchetto V, Pilotto G, Basso G, Zanovello P, Amadori A, Tosello V.

Haematologica. 2018 Feb;103(2):266-277. doi: 10.3324/haematol.2017.170431. Epub 2017 Nov 23.

7.

Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1.

Tosi A, Dalla Santa S, Cappuzzello E, Marotta C, Walerych D, Del Sal G, Zanovello P, Sommaggio R, Rosato A.

Oncoimmunology. 2017 Apr 5;6(8):e1313371. doi: 10.1080/2162402X.2017.1313371. eCollection 2017. Erratum in: Oncoimmunology. 2017 Dec 4;7(1):e1412885. Walerich, Dawid [corrected to Walerych, Dawid].

8.

Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells.

Cappuzzello E, Sommaggio R, Zanovello P, Rosato A.

Cytokine Growth Factor Rev. 2017 Aug;36:99-105. doi: 10.1016/j.cytogfr.2017.06.003. Epub 2017 Jun 3.

9.

A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors.

Turrini R, Merlo A, Martorelli D, Faè DA, Sommaggio R, Montagner IM, Barbieri V, Marin O, Zanovello P, Dolcetti R, Rosato A.

Oncoimmunology. 2017 Mar 16;6(4):e1304338. doi: 10.1080/2162402X.2017.1304338. eCollection 2017.

10.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EM, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Oct 10;30(4):651. doi: 10.1016/j.ccell.2016.09.009. No abstract available.

11.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AHR, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EMC, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Sep 12;30(3):377-390. doi: 10.1016/j.ccell.2016.08.004. Erratum in: Cancer Cell. 2016 Oct 10;30(4):651.

12.

Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies.

Cappuzzello E, Tosi A, Zanovello P, Sommaggio R, Rosato A.

Oncoimmunology. 2016 Jun 30;5(8):e1199311. doi: 10.1080/2162402X.2016.1199311. eCollection 2016 Aug.

13.

Loss of ZFP36 expression in colorectal cancer correlates to wnt/ ß-catenin activity and enhances epithelial-to-mesenchymal transition through upregulation of ZEB1, SOX9 and MACC1.

Montorsi L, Guizzetti F, Alecci C, Caporali A, Martello A, Atene CG, Parenti S, Pizzini S, Zanovello P, Bortoluzzi S, Ferrari S, Grande A, Zanocco-Marani T.

Oncotarget. 2016 Sep 13;7(37):59144-59157. doi: 10.18632/oncotarget.10828.

14.

A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer.

Montagner IM, Merlo A, Carpanese D, Dalla Pietà A, Mero A, Grigoletto A, Loregian A, Renier D, Campisi M, Zanovello P, Pasut G, Rosato A.

J Control Release. 2016 Aug 28;236:79-89. doi: 10.1016/j.jconrel.2016.06.033. Epub 2016 Jun 26.

15.

A circulating miRNA assay as a first-line test for prostate cancer screening.

Sharova E, Grassi A, Marcer A, Ruggero K, Pinto F, Bassi P, Zanovello P, Zattoni F, D'Agostino DM, Iafrate M, Ciminale V.

Br J Cancer. 2016 Jun 14;114(12):1362-6. doi: 10.1038/bjc.2016.151. Epub 2016 May 26.

16.

Reverse immunoediting: When immunity is edited by antigen.

Merlo A, Dalla Santa S, Dolcetti R, Zanovello P, Rosato A.

Immunol Lett. 2016 Jul;175:16-20. doi: 10.1016/j.imlet.2016.04.015. Epub 2016 Apr 27. Review.

PMID:
27131431
17.

Reconstruction of gene regulatory modules from RNA silencing of IFN-α modulators: experimental set-up and inference method.

Grassi A, Di Camillo B, Ciccarese F, Agnusdei V, Zanovello P, Amadori A, Finesso L, Indraccolo S, Toffolo GM.

BMC Genomics. 2016 Mar 12;17:228. doi: 10.1186/s12864-016-2525-5.

18.

Predictors of immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma: a case report.

Cattelan AM, Mattiolo A, Grassi A, Piano MA, Sasset L, Trevenzoli M, Zanovello P, Calabrò ML.

Infect Agent Cancer. 2016 Feb 3;11:5. doi: 10.1186/s13027-016-0051-3. eCollection 2016.

19.

Human miRNome profiling in colorectal cancer and liver metastasis development.

Perilli L, Pizzini S, Bisognin A, Mandruzzato S, Biasiolo M, Facciolli A, Rossi E, Esposito G, Rugge M, Pilati P, Mocellin S, Nitti D, Bortoluzzi S, Zanovello P.

Genom Data. 2014 Jun 27;2:184-8. doi: 10.1016/j.gdata.2014.06.017. eCollection 2014 Dec.

20.

Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer.

Montagner IM, Merlo A, Carpanese D, Zuccolotto G, Renier D, Campisi M, Pasut G, Zanovello P, Rosato A.

Oncoscience. 2015 Mar 23;2(4):373-81. eCollection 2015.

21.

Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.

Mazzocco M, Martini M, Rosato A, Stefani E, Matucci A, Dalla Santa S, De Sanctis F, Ugel S, Sandri S, Ferrarini G, Cestari T, Ferrari S, Zanovello P, Bronte V, Sartoris S.

Immunology. 2015 Sep;146(1):33-49. doi: 10.1111/imm.12477. Epub 2015 Jun 15.

22.

Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs.

Montagner IM, Merlo A, Zuccolotto G, Renier D, Campisi M, Pasut G, Zanovello P, Rosato A.

PLoS One. 2014 Nov 10;9(11):e112240. doi: 10.1371/journal.pone.0112240. eCollection 2014.

23.

PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models.

Zuccolotto G, Fracasso G, Merlo A, Montagner IM, Rondina M, Bobisse S, Figini M, Cingarlini S, Colombatti M, Zanovello P, Rosato A.

PLoS One. 2014 Oct 3;9(10):e109427. doi: 10.1371/journal.pone.0109427. eCollection 2014.

24.

Functional avidity-driven activation-induced cell death shapes CTL immunodominance.

Dalla Santa S, Merlo A, Bobisse S, Ronconi E, Boldrin D, Milan G, Barbieri V, Marin O, Facchinetti A, Biasi G, Dolcetti R, Zanovello P, Rosato A.

J Immunol. 2014 Nov 1;193(9):4704-11. doi: 10.4049/jimmunol.1303203. Epub 2014 Sep 22.

25.

Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression.

Perilli L, Vicentini C, Agostini M, Pizzini S, Pizzi M, D'Angelo E, Bortoluzzi S, Mandruzzato S, Mammano E, Rugge M, Nitti D, Scarpa A, Fassan M, Zanovello P.

Oncotarget. 2014 Aug 30;5(16):6611-9.

26.

Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase.

Ruggero K, Guffanti A, Corradin A, Sharma VK, De Bellis G, Corti G, Grassi A, Zanovello P, Bronte V, Ciminale V, D'Agostino DM.

J Virol. 2014 Apr;88(7):3612-22. doi: 10.1128/JVI.02823-13. Epub 2014 Jan 8.

27.

Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST).

Alaggio R, Turrini R, Boldrin D, Merlo A, Gambini C, Ferrari A, Dall'igna P, Coffin CM, Martines A, Bonaldi L, De Salvo GL, Zanovello P, Rosato A.

PLoS One. 2013 Nov 26;8(11):e80456. doi: 10.1371/journal.pone.0080456. eCollection 2013.

28.

An integrative framework identifies alternative splicing events in colorectal cancer development.

Bisognin A, Pizzini S, Perilli L, Esposito G, Mocellin S, Nitti D, Zanovello P, Bortoluzzi S, Mandruzzato S.

Mol Oncol. 2014 Feb;8(1):129-41. doi: 10.1016/j.molonc.2013.10.004. Epub 2013 Oct 19.

29.

Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis.

Pizzini S, Bisognin A, Mandruzzato S, Biasiolo M, Facciolli A, Perilli L, Rossi E, Esposito G, Rugge M, Pilati P, Mocellin S, Nitti D, Bortoluzzi S, Zanovello P.

BMC Genomics. 2013 Aug 29;14:589. doi: 10.1186/1471-2164-14-589.

30.

miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis.

Sonda N, Simonato F, Peranzoni E, Calì B, Bortoluzzi S, Bisognin A, Wang E, Marincola FM, Naldini L, Gentner B, Trautwein C, Sackett SD, Zanovello P, Molon B, Bronte V.

Immunity. 2013 Jun 27;38(6):1236-49. doi: 10.1016/j.immuni.2013.06.004.

31.

The microRNA regulatory network in normal- and HTLV-1-transformed T cells.

D'Agostino DM, Zanovello P, Watanabe T, Ciminale V.

Adv Cancer Res. 2012;113:45-83. doi: 10.1016/B978-0-12-394280-7.00002-6. Review.

PMID:
22429852
32.

Paclitaxel-hyaluronan hydrosoluble bioconjugate: mechanism of action in human bladder cancer cell lines.

Montagner IM, Banzato A, Zuccolotto G, Renier D, Campisi M, Bassi P, Zanovello P, Rosato A.

Urol Oncol. 2013 Oct;31(7):1261-9. doi: 10.1016/j.urolonc.2012.01.005. Epub 2012 Feb 16.

PMID:
22341413
33.

Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer.

Turrini R, Merlo A, Dolcetti R, Zanovello P, Rosato A.

Cancer Immunol Immunother. 2011 Nov;60(11):1639-45. doi: 10.1007/s00262-011-1086-3. Epub 2011 Aug 11.

34.

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.

Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, Garrett-Mayer E, Montero AJ, Bronte V, Mandruzzato S.

Blood. 2011 Aug 25;118(8):2254-65. doi: 10.1182/blood-2010-12-325753. Epub 2011 Jul 6.

35.

Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150.

Ghisi M, Corradin A, Basso K, Frasson C, Serafin V, Mukherjee S, Mussolin L, Ruggero K, Bonanno L, Guffanti A, De Bellis G, Gerosa G, Stellin G, D'Agostino DM, Basso G, Bronte V, Indraccolo S, Amadori A, Zanovello P.

Blood. 2011 Jun 30;117(26):7053-62. doi: 10.1182/blood-2010-12-326629. Epub 2011 May 6.

36.

Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization.

Nardo G, Favaro E, Curtarello M, Moserle L, Zulato E, Persano L, Rossi E, Esposito G, Crescenzi M, Casanovas O, Sattler U, Mueller-Klieser W, Biesalski B, Thews O, Canese R, Iorio E, Zanovello P, Amadori A, Indraccolo S.

Cancer Res. 2011 Jun 15;71(12):4214-25. doi: 10.1158/0008-5472.CAN-11-0242. Epub 2011 May 5.

37.

Immune response to Moloney-murine leukemia virus-induced antigens in bone marrow.

Biasi G, Facchinetti A, Cappellari R, Rossi E, Zanovello P.

Immunol Lett. 2011 Jul;138(1):79-85. doi: 10.1016/j.imlet.2011.03.005. Epub 2011 Mar 29.

PMID:
21453727
38.

Immunotherapy for EBV-associated malignancies.

Merlo A, Turrini R, Dolcetti R, Zanovello P, Rosato A.

Int J Hematol. 2011 Mar;93(3):281-293. doi: 10.1007/s12185-011-0782-2. Epub 2011 Feb 19.

PMID:
21336546
39.

Impact of γ-chain cytokines on EBV-specific T cell cultures.

Merlo A, Turrini R, Trento C, Zanovello P, Dolcetti R, Rosato A.

J Transl Med. 2010 Nov 22;8:121. doi: 10.1186/1479-5876-8-121.

40.

Immunogenetic aspects of erosive osteoarthritis of the hand in patients from northern Italy.

Ramonda R, Musacchio E, Campana C, Frigato M, Frallonardo P, Barbieri V, Piccoli A, Valvason C, Bronte V, Zanovello P, Punzi L.

Scand J Rheumatol. 2011 Mar;40(2):139-44. doi: 10.3109/03009742.2010.507216. Epub 2010 Oct 5.

PMID:
20919945
41.

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S, Bronte V.

Immunity. 2010 Jun 25;32(6):790-802. doi: 10.1016/j.immuni.2010.05.010. Epub 2010 Jun 3.

42.

Role of microRNAs in HTLV-1 infection and transformation.

Ruggero K, Corradin A, Zanovello P, Amadori A, Bronte V, Ciminale V, D'Agostino DM.

Mol Aspects Med. 2010 Oct;31(5):367-82. doi: 10.1016/j.mam.2010.05.001. Epub 2010 Jun 17. Review.

PMID:
20600265
43.

Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.

Merlo A, Turrini R, Bobisse S, Zamarchi R, Alaggio R, Dolcetti R, Mautner J, Zanovello P, Amadori A, Rosato A.

J Immunol. 2010 May 15;184(10):5895-902. doi: 10.4049/jimmunol.0902850. Epub 2010 Apr 12.

44.

IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer.

Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, Ugel S, Cingarlini S, Bronte V, Zanovello P, Krampera M, Mosna F, Cestari T, Riviera AP, Brutti N, Barbieri O, Matera L, Tridente G, Colombatti M, Sartoris S.

Vaccine. 2010 Apr 30;28(20):3548-57. doi: 10.1016/j.vaccine.2010.03.007. Epub 2010 Mar 19.

PMID:
20304037
45.

Myeloid-derived suppressor cell heterogeneity and subset definition.

Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V.

Curr Opin Immunol. 2010 Apr;22(2):238-44. doi: 10.1016/j.coi.2010.01.021. Epub 2010 Feb 17. Review.

PMID:
20171075
46.

Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.

Bobisse S, Rondina M, Merlo A, Tisato V, Mandruzzato S, Amendola M, Naldini L, Willemsen RA, Debets R, Zanovello P, Rosato A.

Cancer Res. 2009 Dec 15;69(24):9385-94. doi: 10.1158/0008-5472.CAN-09-0494.

47.

In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.

Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Oelke M, Schneck JP, Bronte V.

Cancer Res. 2009 Dec 15;69(24):9376-84. doi: 10.1158/0008-5472.CAN-09-0400.

48.

Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes.

Ugel S, Scarselli E, Iezzi M, Mennuni C, Pannellini T, Calvaruso F, Cipriani B, De Palma R, Ricci-Vitiani L, Peranzoni E, Musiani P, Zanovello P, Bronte V.

Blood. 2010 Feb 18;115(7):1374-84. doi: 10.1182/blood-2009-07-233270. Epub 2009 Nov 10.

49.

Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate.

Banzato A, Rondina M, Meléndez-Alafort L, Zangoni E, Nadali A, Renier D, Moschini G, Mazzi U, Zanovello P, Rosato A.

Nucl Med Biol. 2009 Jul;36(5):525-33. doi: 10.1016/j.nucmedbio.2009.02.005. Epub 2009 May 8.

PMID:
19520293
50.

IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.

Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V, Zanovello P.

J Immunol. 2009 May 15;182(10):6562-8. doi: 10.4049/jimmunol.0803831.

Supplemental Content

Loading ...
Support Center